Drug intelligence / Profile preview

Hemostasis Mixture

Development stage: Preclinical
Lead developer: Xi'an Xincheng Yida Hospital
Modality: Small Molecules
Administration: Topical

Overview

Hemostasis Mixture, also known as xueyou mixture, is a non-blood product medicine developed for the treatment of hemophilia. It is designed to promote hemostasis, likely by complementing the body's natural clotting mechanisms, as suggested by "the principle of hemostasis complementarity". The specific components and detailed mechanism of action are not publicly disclosed, but it is being investigated for its efficacy and safety in clinical trials.

Brand names: Xueyou Mixture
Other names: xueyou mixture

Beyond the preview

Go deeper on Hemostasis Mixture.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemostasis Mixture.

Explore the full profile